Company Profile · Healthcare

Samsung Biologics Co Ltd

207940 · Korea
Industry
Pharma R&D Outsourcing
Exchange
Korea
Country
Korea
Employees
5,195
Website
samsungbiologics.com
Current Price
1,430,000
Live · Jun 18, 2026
Fair Buy
≤ 1,150,000
Margin-of-safety entry
Baillie Growth Score
47/100
Weak
Intrinsic Value · Three-Tier Range Current price 1,430,000 Live · Within the fair intrinsic-value range

Composite valuation range · conservative 850,000–1,100,000 / fair 1,250,000–1,600,000 / optimistic 1,900,000–2,300,000. At 1,430,000, Within the fair intrinsic-value range.

At publication 1,336,000 (Jun 5, 2026)

Research on this stock
Samsung Biologics Co., Ltd.
207940 · Korea
Hold
Samsung Biologics (207940) Zen Horizon Framework Deep Dive: A Global CDMO Champion Newly Purified by Spin-Off, Where an Excellent Business Meets a Rich Price and Unproven BIOSECURE Upside

Samsung Biologics is the world's largest biologics CDMO, a contract development and manufacturing platform that became a pure-play CDMO after spinning off Samsung Bioepis in November 2025. Its core case rests on world-leading capacity of roughly 780,000 liters, operating margin near 45%, revenue growth above 30%, relationships with 17 of the world's top 20 pharmaceutical companies, and a $21.4B backlog, but the valuation already prices in capacity leadership and BIOSECURE upside that has not yet been proven in orders. Report rating Hold: a top-tier compounder deserves a premium, but at the current price the margin of safety is thin.

Pharma R&D Outsourcing Baillie 47 Jun 5, 2026
About the company

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Financial snapshot
Market cap₩63.28T
Revenue (TTM)₩4.81T
EBITDA₩2.78T
Profit margin39.01%
ROE18.25%
Forward P/E42.37
PEG2.06
52-week range₩1,000,000 – ₩1,000,000

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.